Biodistribution, hypouricemic efficacy and therapeutic mechanism of morin phospholipid complex loaded self-nanoemulsifying drug delivery systems in an experimental hyperuricemic model in rats

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 1, 2016, Pages 14-25

  Zhang, Jinjie ^a   Shuai, Xiao ^a   Li, Jianbo ^a   Xiang, Nanxi ^a   Gong, Tao ^a   Zhang, Zhirong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

hyperuricemic; morin phospholipid complex; renal organic ion transporter; self nanoemulsifying drug delivery system; xanthine oxidase

Indexed keywords

ANTIINFLAMMATORY AGENT; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 9; MORIN; MORIN PHOSPHOLIPID COMPLEX; ORGANIC ANION TRANSPORTER 1; OTERACIL POTASSIUM; UNCLASSIFIED DRUG; URATE TRANSPORTER; URIC ACID; XANTHINE DEHYDROGENASE; XANTHINE OXIDASE; FLAVONOID; NANOMATERIAL; ORGANIC ANION TRANSPORTER; PHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; GENE EXPRESSION; HYPERURICEMIA; KIDNEY; LIVER; LOADING DRUG DOSE; MALE; NANOEMULSION; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; URIC ACID BLOOD LEVEL; ANIMAL; METABOLISM; PHYSIOLOGY; PROCEDURES; WISTAR RAT;

ANIMALS; DRUG DELIVERY SYSTEMS; FLAVONOIDS; HYPERURICEMIA; KIDNEY; LIVER; MALE; NANOSTRUCTURES; ORGANIC ANION TRANSPORTERS; PHOSPHOLIPIDS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; URIC ACID;

EID: 84956770189     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12492     Document Type: Article

References (35)

1. Kuo CF, et al. Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine 2012; 79: 375-378.
2. Arromdee E, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002; 29: 2403-2406.
3. Lioté F,. Hyperuricemia and gout. Curr Rheumatol Rep 2003; 5: 227-234.
4. Nakanishi N, et al. Uric acid: correlation with biological, clinical and behavioral factors in Japanese men. J Epidemiol 1999; 9: 99-106.
5. Chen SY, et al. Clinical features of familial gout and effects of probable genetic association between gout and its related disorders. Metabolism 2001; 50: 1203-1207.
6. Spieker LE, et al. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail 2002; 4: 403-410.
7. Gibson T,. Hyperuricemia, gout and the kidney. Curr Opin Rheumatol 2012; 24: 127-131.
8. Edwards NL,. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008; 75 (Suppl. 5): S13-S16.
9. Puig JG, Martinez MA,. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008; 20: 187-191.
10. Terkeltaub R,. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6: 30-38.
11. Reinders MK, Tim L,. New advances in the treatment of gout: review of pegloticase. Ther Clin Risk Manag 2010; 6: 543-550.
12. Garay RP, et al. Therapeutic perspectives on uricases for gout. Joint Bone Spine 2012; 79: 237-242.
13. Yu Z, et al. The dual actions of morin (3, 5, 7, 2′, 4′-pentahydroxyflavone) as a hypouricemic agent: uricosuric effect and xanthine oxidase inhibitory activity. J Pharmacol Exp Ther 2006; 316: 169-175.
14. Wang C-P, et al. Morin improves urate excretion and kidney function through regulation of renal organic ion transporters in hyperuricemic mice. J Pharm Pharm Sci 2010; 13: 411-427.
15. Cho YM, et al. A 13-week subchronic toxicity study of dietary administered morin in F344 rats. Food Chem Toxicol 2006; 44: 891-897.
16. Zhang J, et al. Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex. Int J Nanomedicine 2011; 6: 3405-3411.
17. Schmittgen TD, et al. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008; 6: 1101-1108.
18. Zhang J, et al. Mechanism of enhanced oral absorption of morin by phospholipid complex based self-nanoemulsifying drug delivery system. Mol Pharmaceut 2015; 12: 504-513.
19. Li JM, et al. Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice. Eur J Pharmacol 2011; 666: 196-204.
20. Pauff JM, Hille R,. Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod 2009; 72: 725-731.
21. Hashimoto S,. A new spectrophotometric assay method of xanthine oxidase in crude tissue homogenate. Anal Biochem 1974; 62: 426-435.
22. Hou YC, et al. Profound difference in pharmacokinetics between morin and its isomer quercetin in rats. J Pharm Pharmacol 2003; 55: 199-203.
23. Nickavar A,. Prevention of renal damage by treating hyperuricemia. Int J Prev Med 2013; 4: 1318-1320.
24. Bellinghieri G, et al. Pharmacological treatment of acute and chronic hyperuricemia in kidney diseased patients. Contrib Nephrol 2005; 147: 149-160.
25. Fang SH, et al. Morin sulfates/glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock. Life Sci 2003; 74: 743-756.
26. Yu Z, et al. Morin (3, 5, 7, 2′, 4′-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. Drug Metab Dispos 2007; 35: 981-986.
27. Enomoto A, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452.
28. Hediger MA, et al. Molecular physiology of urate transport. Physiology 2005; 20: 125-133.
29. Eraly SA, et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 2008; 33: 180-192.
30. Matsuo H, et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. J Hum Genet 2008; 83: 744-751.
31. Graessler J, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum 2006; 54: 292-300.
32. Nigam SK, et al. Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat Rev Nephrol 2007; 3: 443-448.
33. Shi YW, et al. Uricosuric and nephroprotective properties of Ramulus Mori ethanol extract in hyperuricemic mice. J Ethnopharmacol 2012; 143: 896-904.
34. Grover B, et al. Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes. J Pharmacol Exp Ther 2004; 308: 949-956.
35. Rizwan AN, Burckhardt G,. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 2007; 24: 450-470.